Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

VRTX

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:VRTX
DateTimeSourceHeadlineSymbolCompany
10/05/202422:01Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:VRTXVertex Pharmaceuticals Inc
08/05/202422:54Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:VRTXVertex Pharmaceuticals Inc
08/05/202406:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VRTXVertex Pharmaceuticals Inc
07/05/202421:46IH Market NewsDisney Slashes Streaming Losses, UBS shoots up 9% as profit triples expectations, and More in EarningsNASDAQ:VRTXVertex Pharmaceuticals Inc
07/05/202406:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRTXVertex Pharmaceuticals Inc
07/05/202406:01Business WireVertex Reports First Quarter 2024 Financial ResultsNASDAQ:VRTXVertex Pharmaceuticals Inc
06/05/202422:09IH Market NewsIndex Futures Point to Strong Monday Opening, Building on Last Week’s Gains; Oil Prices RiseNASDAQ:VRTXVertex Pharmaceuticals Inc
27/04/202401:43Business WireVertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and OlderNASDAQ:VRTXVertex Pharmaceuticals Inc
23/04/202414:45PR Newswire (Canada)VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETESNASDAQ:VRTXVertex Pharmaceuticals Inc
23/04/202414:45PR Newswire (US)VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETESNASDAQ:VRTXVertex Pharmaceuticals Inc
23/04/202414:45PR Newswire (US)VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETESNASDAQ:VRTXVertex Pharmaceuticals Inc
18/04/202422:00Business WireVertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic PainNASDAQ:VRTXVertex Pharmaceuticals Inc
11/04/202421:24IH Market NewsCostco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More NewsNASDAQ:VRTXVertex Pharmaceuticals Inc
11/04/202406:01Business WireVertex Enters Into Agreement to Acquire Alpine Immune SciencesNASDAQ:VRTXVertex Pharmaceuticals Inc
11/04/202406:01Business WireVertex Enters Into Agreement to Acquire Alpine Immune SciencesNASDAQ:VRTXVertex Pharmaceuticals Inc
10/04/202406:05Business WireVertex to Announce First Quarter 2024 Financial Results on May 6NASDAQ:VRTXVertex Pharmaceuticals Inc
02/04/202402:00PR Newswire (Canada)Vertex annonce que la présentation de drogue nouvelle d'Exagamglogène Autotemcel (exa-cel) a été acceptée pour évaluation prioritaire par Santé Canada pour le traitement de l'anémie falciforme et de la bêta-thalassémie dépendante des transfusionNASDAQ:VRTXVertex Pharmaceuticals Inc
02/04/202402:00PR Newswire (Canada)Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta ThalassemiaNASDAQ:VRTXVertex Pharmaceuticals Inc
01/04/202423:00Business WireVertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney DiseaseNASDAQ:VRTXVertex Pharmaceuticals Inc
21/03/202423:00Business WireVertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)NASDAQ:VRTXVertex Pharmaceuticals Inc
28/02/202409:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
28/02/202409:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
28/02/202408:59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
28/02/202408:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
28/02/202408:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
28/02/202408:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
28/02/202408:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
28/02/202408:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
28/02/202408:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
27/02/202405:19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VRTXVertex Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:VRTX